Intranasal T-LysYal® for patients with allergic, non-allergic, and mixed rhinitis

Ancillary therapy of intranasal T-LysYal^® for patients with allergic, non-allergic, and mixed rhinitis.

Article specifications

This clinical study was published in 2016 in Journal of J Biol Regul Homeost Agents. (IF 2015:1.36) by Italian specialists. This randomized study investigated whether intranasal T-LysYal^® (rinoLysYal^®, Farmigea, Italy) was able to reduce symptom severity, endoscopic features, and nasal cytology in 89 patients with AR, NAR, and MR. Patients were treated with intranasal T-LysYal^® or isotonic saline solution as adjunctive therapy to nasal corticosteroid and oral antihistamine for 4 weeks.

 

Results

Intranasal T-LysYal^® treatment significantly reduced the quote of patients with symptoms, endoscopic features, and inflammatory cells. In conclusion, the present study demonstrates that intranasal T-LysYal^® is able, as ancillary therapy, to significantly improve patients with AR, NAR, and MR, and its effect is long lasting.